0
     

Report Added
Report already added
Immunoassay Market by Product (Reagents & Kits, Analyzers), Technology (ELISA, Rapid Test, Western Blotting, ELISPOT), Specimen (Blood, Saliva), Application (Infectious Diseases, Oncology), End User (Hospitals & Clinics) - Global Forecasts to 2027

Immunoassay Market by Product (Reagents & Kits, Analyzers), Technology (ELISA, Rapid Test, Western Blotting, ELISPOT), Specimen (Blood, Saliva), Application (Infectious Diseases, Oncology), End User (Hospitals & Clinics) - Global Forecasts to 2027

The global immunoassay market is valued at an estimated USD 40.2 billion in 2022 and is projected to reach USD 49.6 billion by 2027, at a CAGR of 4.3% during the forecast period. Market growth is driven by factors such as the increasing incidence of chronic and infectious diseases, advancements in systems and technologies, growth in the biotechnology and biopharmaceutical industries, supportive government policies, increasing adoption of immunoassay-based POC testing and rapid testing, and increasing drug and alcohol abuse and stringent laws mandating drug and alcohol testing.

“The reagents & kits to register the largest share of the immunoassay market, by product”

The global immunoassay market is segmented into reagents & kits and analyzers based on product. Market growth is largely driven by the large consumption of reagents & kits for various procedures along with the rising volume of immunoassay-based tests performed worldwide.

“Rapid Tests segment to grow at a considerable rate among technology during the forecast period”

The immunoassay market is segmented into ELISA, rapid tests, ELISpot, western blotting, radioimmunoassays, and other technologies. Rapid tests are used to test donated blood for the detection of HIV, HCV, HBV, and HCG antibodies. Rapid tests are preferred as a preferred method in POC diagnosis, particularly in emergency and primary care settings.

“The blood segment accounted to grow at the fastest rate, by specimen, in 2021”

Based on specimens, the immunoassay market is segmented into blood, saliva, urine, and other specimens. In 2021, blood specimens is anticipated to witness growth at the highest rate owing to increasing incidence of chronic and infectious diseases and rise in the rate of blood donations.

“Infectious diseases segment to register the highest growth rate among applications during the forecast period”

The global immunoassay market is segmented into infectious diseases, endocrinology, oncology, bone & mineral disorders, cardiology, blood screening, autoimmune disorders, allergy diagnostics, toxicology, newborn screening, and other applications. The application segment of infectious diseases is anticipated to grow that the highest CAGR during the forecast period, owing to the rise in the number of products being launched for its diagnosis.

“Among the end users, the hospitals & clinics segment anticipated to grow at a significant rate during the forecast period”

The rise in the prevalence of chronic and infectious diseases has led to significant growth of the hospitals & clinics end user segment. The segment is also consider to register highest growth rate during the forecast period.

“The Asia Pacific market is expected to grow at the highest CAGR during the forecast period”

The global immunoassay market is segmented into five regions - North America, Europe, the Asia Pacific, Middle East & Africa, and Latin America. The Asia Pacific region is expected to witness the highest growth in the immunoassay market during the forecast period. The high growth in this region can primarily be attributed to the increasing geriatric population, and high disease burden of chronic disorders along with developing healthcare infrastructure in Asian countries such as India and China.

The primary interviews conducted for this report can be categorized as follows:
•By Company Type: Tier 1 - 28%, Tier 2 - 41%, and Tier 3 - 31%
•By Designation: C-level - 30%, D-level - 34%, and Others - 36%
•By Region: North America - 38%, Europe - 27%, Asia Pacific - 18%, Middle East & Africa – 11%, and Latin America – 6%

Lists of Companies Profiled in the Report:
•Abbott Laboratories (US)
•F. Hoffmann-La Roche (Switzerland)
•Siemens Healthineers (Germany)
•Thermo Fisher Scientific (US)
•Danaher Corporation (US)
•PerkinElmer (US)
•Becton, Dickinson and Company (US)
•DiaSorin S.p.A. (Italy)
•Bio- Rad Laboratories (US)
•Quidel Corporation (US)
•Ortho Clinical Diagnostics Holdings (US)
•bioMérieux (France)
•QIAGEN (Netherlands)
•Sysmex Corporation (Japan)
•Agilent Technologies (US)
•Mindray Medical International Company (China)
•Merck KGaA (Germany)
•Meridian Bioscience (US)
•Bio-Techne (US)
•Cellabs (Australia)
•Abnova Corporation (Taiwan)
•J. Mitra & Co. Pvt. Ltd. (India)
•Tosoh Corporation (Japan)
•Cell Sciences (US)
•Enzo Biochem (US)
•Creative Diagnostics (US)
•Boster Biological Technology (US)
•Elabscience (US)
•WAK-Chemie Medical (Germany)
•Sera Care (US)
•Epitope Diagnostics (US)
•Kamiya Biomedical Company (US)
•Gyros Protein Technologies (Sweden)
•Trivitron Healthcare (India)
•InBios International (US).

Research Coverage:
This report provides a detailed picture of the global immunoassay market. It aims at estimating the size and future growth potential of the market across different segments, such as product, technology, specimen, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall immunoassay market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities and challenges.
Table of Contents

1 INTRODUCTION 44 1.1 STUDY OBJECTIVES 44 1.2 MARKET DEFINITION 44 1.2.1 INCLUSIONS & EXCLUSIONS 44 1.3 MARKET SCOPE 45 FIGURE 1 IMMUNOASSAY MARKET 45 1.3.1 YEARS CONSIDERED 46 1.4 CURRENCY CONSIDERED 46 1.5 STAKEHOLDERS 46 1.6 SUMMARY OF CHANGES 47 2 RESEARCH METHODOLOGY 48 2.1 RESEARCH DATA 48 FIGURE 2 RESEARCH DESIGN 48 2.1.1 SECONDARY DATA 49 2.1.1.1 Secondary sources 50 2.1.2 PRIMARY DATA 50 2.1.2.1 Key data from primary sources 51 2.1.2.2 Key industry insights 52 FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 53 FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 53 2.2 MARKET SIZE ESTIMATION 53 2.2.1 BOTTOM-UP APPROACH 54 FIGURE 5 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 54 FIGURE 6 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 55 FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 55 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 56 FIGURE 8 DATA TRIANGULATION METHODOLOGY 56 2.4 MARKET SHARE ANALYSIS 57 2.5 STUDY ASSUMPTIONS 57 2.6 RISK ASSESSMENT 57 TABLE 1 RISK ASSESSMENT: IMMUNOASSAY MARKET 57 2.7 LIMITATIONS 58 2.7.1 METHODOLOGY-RELATED LIMITATIONS 58 2.7.2 SCOPE-RELATED LIMITATIONS 58 2.8 GROWTH RATE ASSUMPTIONS 58 3 EXECUTIVE SUMMARY 59 FIGURE 9 IMMUNOASSAY MARKET, BY PRODUCT, 2022 VS. 2027 (USD BILLION) 59 FIGURE 10 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD BILLION) 60 FIGURE 11 IMMUNOASSAY MARKET, BY SPECIMEN, 2022 VS. 2027 (USD BILLION) 61 FIGURE 12 IMMUNOASSAY MARKET, BY APPLICATION, 2022 VS. 2027 (USD BILLION) 62 FIGURE 13 IMMUNOASSAY MARKET, BY END USER, 2022 VS. 2027 (USD BILLION) 63 FIGURE 14 GEOGRAPHICAL SNAPSHOT OF IMMUNOASSAY MARKET 64 4 PREMIUM INSIGHTS 65 4.1 IMMUNOASSAY MARKET OVERVIEW 65 FIGURE 15 RISING DISEASE INCIDENCE AND TECHNOLOGICAL ADVANCEMENTS—KEY DRIVERS OF MARKET GROWTH 65 4.2 NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT & COUNTRY (2021) 66 FIGURE 16 REAGENTS & KITS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2021 66 4.3 IMMUNOASSAY MARKET: GEOGRAPHICAL SNAPSHOT 67 FIGURE 17 CHINA & INDIA TO WITNESS HIGHEST GROWTH RATES DURING FORECAST PERIOD 67 4.4 IMMUNOASSAY MARKET: GEOGRAPHIC MIX 68 FIGURE 18 APAC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 68 4.5 IMMUNOASSAY MARKET: DEVELOPED VS. DEVELOPING MARKETS 69 FIGURE 19 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD 69 5 MARKET OVERVIEW 70 5.1 INTRODUCTION 70 5.2 MARKET DYNAMICS 70 FIGURE 20 IMMUNOASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 70 5.2.1 DRIVERS 71 5.2.1.1 Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis 71 FIGURE 21 INCIDENCE OF DIABETES, BY REGION, 2019 VS. 2030 VS. 2045 (MILLION) 71 TABLE 2 GLOBAL INCIDENCE OF INFECTIOUS DISEASES 72 5.2.1.1.1 Increasing use of immunoassays in oncology 72 TABLE 3 GLOBAL INCIDENCE OF TOP CANCERS IN MEN, 2020 73 TABLE 4 GLOBAL INCIDENCE OF TOP CANCERS IN WOMEN, 2020 73 5.2.1.1.2 Immunoassays for COVID-19 and other viral diagnostics 74 5.2.1.1.3 Immunoassays in drug detection and other diagnostic applications 74 TABLE 5 DETECTION OF DRUGS BY URINE TESTING 75 5.2.1.1.4 Growing geriatric population 75 FIGURE 22 GLOBAL AGING POPULATION, BY REGION, 2019 VS. 2050 (MILLION) 75 5.2.1.2 Advancements in systems and technologies 76 5.2.1.3 Growth in biotechnology and biopharmaceutical industries 77 5.2.1.4 Increasing adoption of immunoassay-based POC testing and rapid testing 77 TABLE 6 RECENT WAIVERS OF MARKET PRODUCTS 78 5.2.1.5 Supportive government policies 79 5.2.1.6 Increasing drug and alcohol abuse and stringent laws mandating drug and alcohol testing 79 5.2.2 RESTRAINTS 80 5.2.2.1 Stringent requirements for approval of immunoassay instruments and consumables 80 5.2.2.2 Technical hurdles of immunoassay kits 80 5.2.3 OPPORTUNITIES 81 5.2.3.1 Growth opportunities in emerging economies 81 5.2.3.2 Importance of companion diagnostics 82 TABLE 7 COMPANION DIAGNOSTIC ASSAYS APPROVED AND LAUNCHED 83 5.2.3.3 Development of condition-specific biomarkers and tests 83 TABLE 8 NEW TESTS LAUNCHED BY KEY PLAYERS 84 5.2.3.4 Integration of microfluidics in immunoassays 84 TABLE 9 LAB-ON-A-CHIP IMMUNOASSAYS/DEVICES/SYSTEMS OFFERED BY PLAYERS 85 5.2.3.5 Improving immunoassay diagnostic technologies 85 5.2.4 CHALLENGES 85 5.2.4.1 Design challenges, complexities, and quality of antibodies 85 5.2.4.2 Dearth of skilled professionals 86 5.2.4.3 Unfavorable reimbursement scenario 86 5.2.4.4 Financial hurdles faced by physicians 86 5.3 REGULATORY OVERVIEW 87 5.3.1 US 87 TABLE 10 US: CLASSIFICATION OF IMMUNOASSAY PRODUCTS 87 FIGURE 23 US: REGULATORY PROCESS FOR IVD DEVICES 88 5.3.2 CANADA 89 FIGURE 24 CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA 89 5.3.3 EUROPE 89 TABLE 11 EUROPE: CLASSIFICATION OF IVD DEVICES 89 5.3.4 JAPAN 90 5.3.4.1 Japan: Regulatory process for IVD devices 90 TABLE 12 JAPAN: CLASSIFICATION OF IVD REAGENTS IN JAPAN 91 TABLE 13 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 91 5.3.5 CHINA 91 TABLE 14 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 91 5.3.6 INDIA 92 5.3.6.1 India: Regulatory process for IVD devices 92 5.3.7 INDONESIA 93 TABLE 15 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES 93 5.3.8 RUSSIA 93 TABLE 16 RUSSIA: CLASSIFICATION OF IVD DEVICES 94 5.3.9 SAUDI ARABIA 94 TABLE 17 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 94 5.3.10 MEXICO 94 5.3.10.1 Mexico: Regulatory process for IVD devices 95 TABLE 18 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 95 5.3.11 BRAZIL 96 5.3.11.1 Brazil: Regulatory process for IVD devices 96 5.3.12 SOUTH KOREA 96 TABLE 19 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 96 5.3.13 MIDDLE EAST 97 5.3.14 AFRICA 97 5.4 TECHNOLOGY ANALYSIS 97 TABLE 20 CONVENTIONAL IMMUNOASSAY METHODS AND TECHNIQUES 97 TABLE 21 RECENT PRODUCT LAUNCHES WITH ADVANCED TECHNOLOGIES IN IMMUNOASSAY MARKET 98 5.5 TRADE ANALYSIS 98 5.5.1 TRADE ANALYSIS FOR IMMUNOASSAYS 98 TABLE 22 IMPORT DATA FOR HS CODE 902750, BY COUNTRY, 2017–2021 (USD MILLION) 99 TABLE 23 EXPORT DATA FOR HS CODE 902750, BY COUNTRY, 2016–2020 (USD MILLION) 99 5.6 PATENT ANALYSIS 100 5.7 VALUE CHAIN ANALYSIS 101 FIGURE 25 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 101 5.8 SUPPLY CHAIN ANALYSIS 102 FIGURE 26 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES 102 5.9 ECOSYSTEM ANALYSIS OF IMMUNOASSAY MARKET 103 FIGURE 27 ECOSYSTEM ANALYSIS OF IMMUNOASSAY MARKET 103 5.9.1 ROLE IN ECOSYSTEM 103 5.9.2 KEY PLAYERS OPERATING IN IMMUNOASSAY MARKET 104 5.10 PORTER’S FIVE FORCES ANALYSIS 105 TABLE 24 HIGH CONSOLIDATION IN MARKET TO RESTRICT ENTRY OF NEW PLAYERS 105 5.10.1 DEGREE OF COMPETITION 105 5.10.2 BARGAINING POWER OF SUPPLIERS 105 5.10.3 BARGAINING POWER OF BUYERS 105 5.10.4 THREAT FROM SUBSTITUTES 105 5.10.5 THREAT FROM NEW ENTRANTS 106 5.11 KEY CONFERENCES & EVENTS IN 2022 106 TABLE 25 LIST OF CONFERENCES & EVENTS 106 5.12 PRICING ANALYSIS 107 TABLE 26 IMMUNOASSAY: PRICE RANGE FOR IMMUNOASSAY PRODUCTS 107 5.13 KEY STAKEHOLDERS & BUYING CRITERIA 108 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 108 FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 108 TABLE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS 108 5.13.2 BUYING CRITERIA 109 FIGURE 29 KEY BUYING CRITERIA FOR TOP END USERS 109 TABLE 28 KEY BUYING CRITERIA, BY END USER 109 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 110 5.15 SCENARIO-BASED MARKET ASSESSMENT 111 5.15.1 IMMUNOASSAY MARKET FORECAST 111 FIGURE 30 PESSIMISTIC SCENARIO 111 FIGURE 31 OPTIMISTIC SCENARIO 111 FIGURE 32 REALISTIC SCENARIO 112 6 IMMUNOASSAY MARKET, BY PRODUCT 113 6.1 INTRODUCTION 114 TABLE 29 IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 114 6.2 REAGENTS & KITS 114 TABLE 30 IMMUNOASSAY REAGENTS & KITS AVAILABLE IN MARKET 115 TABLE 31 IMMUNOASSAY REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION) 116 TABLE 32 IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 116 6.2.1 ELISA REAGENTS & KITS 117 6.2.1.1 Wide usage in basic research and high-throughput screening 117 TABLE 33 ELISA REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION) 118 6.2.2 RAPID TEST REAGENTS & KITS 118 6.2.2.1 High demand for rapid test reagents & kits in remote areas to drive growth 118 TABLE 34 RAPID TEST REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION) 119 6.2.3 ELISPOT REAGENTS & KITS 119 6.2.3.1 High sensitivity, functionality, and adaptability of ELISpot technology to drive demand 119 TABLE 35 ELISPOT REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION) 120 6.2.4 WESTERN BLOT REAGENTS & KITS 120 6.2.4.1 Gold standard for result confirmation promotes Western blotting reagents & kits 120 TABLE 36 WESTERN BLOT REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION) 121 6.2.5 OTHER REAGENTS & KITS 121 TABLE 37 OTHER IMMUNOASSAY REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION) 122 6.3 ANALYZERS 122 TABLE 38 IMMUNOASSAY ANALYZERS AVAILABLE IN MARKET 123 TABLE 39 IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2020–2027 (USD MILLION) 124 6.3.1 IMMUNOASSAY ANALYZERS MARKET, BY TYPE 124 TABLE 40 IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 125 6.3.1.1 Open-ended systems 125 6.3.1.1.1 Flexibility and wide availability make open-ended systems popular among users 125 TABLE 41 OPEN-ENDED SYSTEMS MARKET, BY REGION, 2020–2027 (USD MILLION) 125 6.3.1.2 Closed-ended systems 126 6.3.1.2.1 High precision and automation are key features of closed-ended systems 126 TABLE 42 CLOSED-ENDED SYSTEMS MARKET, BY REGION, 2020–2027 (USD MILLION) 126 6.3.2 IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE 126 TABLE 43 IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 126 6.3.2.1 Rental purchase 127 6.3.2.1.1 Convenience and lack of liability for end users drive preference for device rental 127 TABLE 44 RENTAL PURCHASE IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2020–2027 (USD MILLION) 127 6.3.2.2 Outright purchase 128 6.3.2.2.1 Outright purchase is favored by government organizations, big companies, and CROs 128 TABLE 45 OUTRIGHT PURCHASE IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2020–2027 (USD MILLION) 128 7 IMMUNOASSAY MARKET, BY TECHNOLOGY 129 7.1 INTRODUCTION 130 TABLE 46 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 130 7.2 ELISA 130 TABLE 47 KEY ELISA SYSTEMS AVAILABLE IN MARKET 131 TABLE 48 IMMUNOASSAY MARKET FOR ELISA, BY REGION, 2020–2027 (USD MILLION) 132 7.2.1 ELISA MARKET, BY GENERATION 132 TABLE 49 IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 132 7.2.1.1 Third-generation & above 133 7.2.1.1.1 Third- & fourth-gen ELISA show high specificity and accuracy 133 TABLE 50 THIRD-GENERATION & ABOVE ELISA MARKET, BY REGION, 2020–2027 (USD MILLION) 133 7.2.1.2 Second-generation & below 134 7.2.1.2.1 Cost-effectiveness of first- and second-generation tests supports their use 134 TABLE 51 SECOND-GENERATION & BELOW ELISA MARKET, BY REGION, 2020–2027 (USD MILLION) 134 7.2.2 ELISA MARKET, BY TYPE 135 TABLE 52 IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 135 7.2.2.1 CLIA 135 7.2.2.1.1 CLIA holds largest share of ELISA market, by type 135 TABLE 53 CLIA MARKET, BY REGION, 2020–2027 (USD MILLION) 136 7.2.2.2 IFA 136 7.2.2.2.1 IFA is used to diagnose antibodies against infectious pathogens 136 TABLE 54 IFA MARKET, BY REGION, 2020–2027 (USD MILLION) 137 7.2.2.3 Colorimetric immunoassays 137 7.2.2.3.1 Introduction of advanced techniques will support market growth 137 TABLE 55 COLORIMETRIC IMMUNOASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION) 138 7.3 RAPID TESTS 138 7.3.1 WIDE USE OF RAPID TESTS IN EMERGING COUNTRIES OR AREAS WITH LIMITED TECHNOLOGY ACCESS TO DRIVE GROWTH 138 TABLE 56 KEY RAPID TESTS AVAILABLE IN MARKET 138 TABLE 57 IMMUNOASSAY MARKET FOR RAPID TESTS, BY REGION, 2020–2027 (USD MILLION) 139 7.4 WESTERN BLOTTING 140 7.4.1 WIDE USE IN RESULT CONFIRMATION AND ANTIBODY DETECTION RESPONSIBLE FOR MARKET GROWTH 140 TABLE 58 WESTERN BLOTTING SYSTEMS AVAILABLE IN MARKET 140 TABLE 59 IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY REGION, 2020–2027 (USD MILLION) 140 7.5 RADIOIMMUNOASSAYS 141 7.5.1 HIGH USAGE OF RIA FOR DIAGNOSIS AND DRUG TESTING TO DRIVE GROWTH 141 TABLE 60 IMMUNOASSAY MARKET FOR RADIOIMMUNOASSAYS, BY REGION, 2020–2027 (USD MILLION) 141 7.6 ELISPOT 141 7.6.1 HIGH SENSITIVITY, SPECIFICITY, AND VERSATILITY OF ELISPOT DRIVE ADOPTION OF ASSAYS 141 TABLE 61 IMMUNOASSAY MARKET FOR ELISPOT, BY REGION, 2020–2027 (USD MILLION) 142 7.7 OTHER TECHNOLOGIES 142 TABLE 62 IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION) 143 8 IMMUNOASSAY MARKET, BY SPECIMEN 144 8.1 INTRODUCTION 145 TABLE 63 IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 145 8.2 BLOOD 145 8.2.1 HIGH RELIABILITY OF BLOOD TESTS WILL ENSURE STABLE MARKET GROWTH 145 TABLE 64 IMMUNOASSAY MARKET FOR BLOOD SPECIMENS, BY REGION, 2020–2027 (USD MILLION) 146 8.3 SALIVA 147 8.3.1 CONVENIENCE AND APPLICATIONS OF SALIVA TESTS TO SUPPORT MARKET GROWTH 147 TABLE 65 IMMUNOASSAY MARKET FOR SALIVA SPECIMENS, BY REGION, 2020–2027 (USD MILLION) 147 8.4 URINE 148 8.4.1 USE IN LAW ENFORCEMENT AND DRUG TESTING APPLICATIONS DRIVES DEMAND FOR URINE-BASED TESTS 148 TABLE 66 IMMUNOASSAY MARKET FOR URINE SPECIMENS, BY REGION, 2020–2027 (USD MILLION) 148 8.5 OTHER SPECIMENS 149 TABLE 67 IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY REGION, 2020–2027 (USD MILLION) 149 9 IMMUNOASSAY MARKET, BY APPLICATION 150 9.1 INTRODUCTION 151 TABLE 68 IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 151 9.2 INFECTIOUS DISEASES 152 9.2.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH 152 TABLE 69 IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020–2027 (USD MILLION) 152 9.3 ENDOCRINOLOGY 153 9.3.1 RISING GLOBAL DIABETES INCIDENCE WILL DRIVE DEMAND FOR IMMUNOASSAYS 153 TABLE 70 IMMUNOASSAY MARKET FOR ENDOCRINOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 153 9.4 CARDIOLOGY 154 9.4.1 HIGH BURDEN OF CVD TO SUPPORT MARKET GROWTH 154 TABLE 71 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR CARDIOLOGY APPLICATIONS 154 TABLE 72 IMMUNOASSAY MARKET FOR CARDIOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 155 9.5 AUTOIMMUNE DISORDERS 155 9.5.1 RISING ECONOMIC BURDEN OF AUTOIMMUNE DISORDER TREATMENT—A KEY FACTOR DRIVING MARKET GROWTH 155 TABLE 73 IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2020–2027 (USD MILLION) 156 9.6 ALLERGY DIAGNOSTICS 156 9.6.1 GROWING PREVALENCE OF ALLERGIES TO INCREASE DEMAND FOR IMMUNOASSAYS 156 TABLE 74 IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION) 157 9.7 ONCOLOGY 157 9.7.1 RISING BURDEN OF CANCER—A POSITIVE INDICATOR OF MARKET GROWTH 157 TABLE 75 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION) 158 TABLE 76 IMMUNOASSAY MARKET FOR ONCOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 159 9.8 BONE & MINERAL DISORDERS 159 9.8.1 HIGH DISORDER PREVALENCE INDICATES STRONG GROWTH OPPORTUNITIES FOR IMMUNOASSAYS 159 TABLE 77 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR BONE & MINERAL DISORDER DIAGNOSIS 160 TABLE 78 IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2020–2027 (USD MILLION) 160 9.9 TOXICOLOGY 160 9.9.1 DRUG ABUSE AND ILLICIT DRUG CONSUMPTION ENSURE DEMAND FOR IMMUNOASSAYS IN TOXICOLOGY 160 TABLE 79 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR DRUG MONITORING 161 TABLE 80 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR DRUGS-OF-ABUSE/TOXICOLOGY ASSAYS 161 TABLE 81 IMMUNOASSAY MARKET FOR TOXICOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 162 9.10 BLOOD SCREENING 162 9.10.1 RISING BLOOD DONATION VOLUMES FAVOR DEMAND FOR IMMUNOASSAYS 162 TABLE 82 IMMUNOASSAY MARKET FOR BLOOD SCREENING APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 163 9.11 NEWBORN SCREENING 163 9.11.1 IMMUNOASSAYS USED AS FIRST-TIER NEWBORN SCREENING PROTOCOL—A MAJOR DRIVING FACTOR 163 TABLE 83 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR NEWBORN SCREENING 164 TABLE 84 IMMUNOASSAY MARKET FOR NEWBORN SCREENING APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 165 9.12 OTHER APPLICATIONS 165 TABLE 85 IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 166 10 IMMUNOASSAY MARKET, BY END USER 167 10.1 INTRODUCTION 168 TABLE 86 IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 168 10.2 HOSPITALS & CLINICS 168 10.2.1 GROWING PATIENT POPULATION AND TESTING VOLUMES DRIVE MARKET GROWTH 168 TABLE 87 IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2027 (USD MILLION) 169 10.3 CLINICAL LABORATORIES 170 10.3.1 RISING CLINICAL TEST VOLUMES AND REQUIREMENTS SUPPORT USE OF IMMUNOASSAYS IN CLINICAL LABS 170 TABLE 88 IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 171 10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS 171 10.4.1 GROWING DRUG DISCOVERY AND CLINICAL STUDY ACTIVITY DRIVES DEMAND FOR IMMUNOASSAYS IN PHARMA-BIOTECH INDUSTRY 171 TABLE 89 IMMUNOASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS, BY REGION, 2020–2027 (USD MILLION) 172 10.5 HOME CARE SETTINGS 172 10.5.1 RELIANCE ON AT-HOME TESTS AND POC DIAGNOSTICS BOOSTS MARKET GROWTH 172 TABLE 90 IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY REGION, 2020–2027 (USD MILLION) 173 10.6 BLOOD BANKS 173 10.6.1 RISING DEMAND FOR BLOOD AND GROWING BLOOD DONATION VOLUMES DRIVE USE OF IMMUNOASSAYS FOR SCREENING 173 TABLE 91 IMMUNOASSAY MARKET FOR BLOOD BANKS, BY REGION, 2020–2027 (USD MILLION) 174 10.7 RESEARCH & ACADEMIC LABORATORIES 174 10.7.1 RISING NUMBER OF COLLEGES & UNIVERSITIES DRIVES MARKET GROWTH 174 TABLE 92 IMMUNOASSAY MARKET FOR RESEARCH & ACADEMIC LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 175 11 IMMUNOASSAY MARKET, BY REGION 176 11.1 INTRODUCTION 177 TABLE 93 IMMUNOASSAY MARKET, BY REGION, 2020–2027 (USD MILLION) 177 11.2 NORTH AMERICA 178 FIGURE 33 NORTH AMERICA: IMMUNOASSAY MARKET SNAPSHOT 179 TABLE 94 NORTH AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 180 TABLE 95 NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 180 TABLE 96 NORTH AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 181 TABLE 97 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 181 TABLE 98 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 182 TABLE 99 NORTH AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 182 TABLE 100 NORTH AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 183 TABLE 101 NORTH AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 183 TABLE 102 NORTH AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 184 TABLE 103 NORTH AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 184 TABLE 104 NORTH AMERICA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 185 11.2.1 US 185 11.2.1.1 US holds largest share in North American market 185 TABLE 105 US: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 186 TABLE 106 US: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 187 TABLE 107 US: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 187 TABLE 108 US: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 188 TABLE 109 US: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 188 TABLE 110 US: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 189 TABLE 111 US: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 189 TABLE 112 US: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 190 TABLE 113 US: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 190 TABLE 114 US: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 191 11.2.2 CANADA 191 11.2.2.1 Initiatives undertaken by government bodies to support growth of market in Canada 191 TABLE 115 CANADA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 192 TABLE 116 CANADA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 193 TABLE 117 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 193 TABLE 118 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 194 TABLE 119 CANADA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 194 TABLE 120 CANADA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 195 TABLE 121 CANADA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 195 TABLE 122 CANADA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 196 TABLE 123 CANADA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 196 TABLE 124 CANADA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 197 11.3 EUROPE 197 TABLE 125 EUROPE: IMMUNOASSAY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 198 TABLE 126 EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 199 TABLE 127 EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 199 TABLE 128 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 200 TABLE 129 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 200 TABLE 130 EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 201 TABLE 131 EUROPE: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 201 TABLE 132 EUROPE: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 202 TABLE 133 EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 202 TABLE 134 EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 203 TABLE 135 EUROPE: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 203 11.3.1 GERMANY 204 11.3.1.1 Germany holds largest share of EU immunoassay market 204 TABLE 136 GERMANY: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 205 TABLE 137 GERMANY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 205 TABLE 138 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 206 TABLE 139 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 206 TABLE 140 GERMANY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 207 TABLE 141 GERMANY: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 207 TABLE 142 GERMANY: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 208 TABLE 143 GERMANY: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 208 TABLE 144 GERMANY: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 209 TABLE 145 GERMANY: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 209 11.3.2 ITALY 210 11.3.2.1 Growing geriatric population and increasing support for research to support market growth 210 TABLE 146 ITALY: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 210 TABLE 147 ITALY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 211 TABLE 148 ITALY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 211 TABLE 149 ITALY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 212 TABLE 150 ITALY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 212 TABLE 151 ITALY: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 213 TABLE 152 ITALY: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 213 TABLE 153 ITALY: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 214 TABLE 154 ITALY: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 214 TABLE 155 ITALY: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 215 11.3.3 FRANCE 215 11.3.3.1 Rising use of POC testing and favorable reimbursement policies make France a lucrative market 215 TABLE 156 FRANCE: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 216 TABLE 157 FRANCE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 216 TABLE 158 FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 217 TABLE 159 FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 217 TABLE 160 FRANCE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 218 TABLE 161 FRANCE: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 218 TABLE 162 FRANCE: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 219 TABLE 163 FRANCE: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 219 TABLE 164 FRANCE: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 220 TABLE 165 FRANCE: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 220 11.3.4 SPAIN 221 11.3.4.1 Increasing adoption of technologically advanced immunoassay systems makes Spain a relatively large market 221 TABLE 166 SPAIN: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 221 TABLE 167 SPAIN: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 222 TABLE 168 SPAIN: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 222 TABLE 169 SPAIN: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 223 TABLE 170 SPAIN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 223 TABLE 171 SPAIN: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 224 TABLE 172 SPAIN: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 224 TABLE 173 SPAIN: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 225 TABLE 174 SPAIN: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 225 TABLE 175 SPAIN: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 226 11.3.5 UK 226 11.3.5.1 Government support for disease diagnostics and favorable investment scenario drive market in UK 226 TABLE 176 UK: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 227 TABLE 177 UK: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 228 TABLE 178 UK: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 228 TABLE 179 UK: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 229 TABLE 180 UK: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 229 TABLE 181 UK: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 230 TABLE 182 UK: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 230 TABLE 183 UK: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 231 TABLE 184 UK: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 231 TABLE 185 UK: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 232 11.3.6 RUSSIA 232 11.3.6.1 Lack of reimbursement and delays in approval may hinder market growth 232 TABLE 186 RUSSIA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 233 TABLE 187 RUSSIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 233 TABLE 188 RUSSIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 234 TABLE 189 RUSSIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 234 TABLE 190 RUSSIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 235 TABLE 191 RUSSIA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 235 TABLE 192 RUSSIA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 236 TABLE 193 RUSSIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 236 TABLE 194 RUSSIA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 237 TABLE 195 RUSSIA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 237 11.3.7 REST OF EUROPE 238 TABLE 196 REST OF EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 238 TABLE 197 REST OF EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 239 TABLE 198 REST OF EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 239 TABLE 199 REST OF EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 240 TABLE 200 REST OF EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 240 TABLE 201 REST OF EUROPE: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 241 TABLE 202 REST OF EUROPE: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 241 TABLE 203 REST OF EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 242 TABLE 204 REST OF EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 242 TABLE 205 REST OF EUROPE: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 243 11.4 ASIA PACIFIC 243 FIGURE 34 ASIA PACIFIC: IMMUNOASSAY MARKET SNAPSHOT 244 TABLE 206 ASIA PACIFIC: IMMUNOASSAY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 245 TABLE 207 ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 245 TABLE 208 ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 246 TABLE 209 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 246 TABLE 210 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 247 TABLE 211 ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 247 TABLE 212 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 248 TABLE 213 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 248 TABLE 214 ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 249 TABLE 215 ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 249 TABLE 216 ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 250 11.4.1 JAPAN 250 11.4.1.1 Investments in healthcare technology and research to support growth in Japan 250 TABLE 217 JAPAN: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 251 TABLE 218 JAPAN: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 251 TABLE 219 JAPAN: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 252 TABLE 220 JAPAN: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 252 TABLE 221 JAPAN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 253 TABLE 222 JAPAN: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 253 TABLE 223 JAPAN: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 254 TABLE 224 JAPAN: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 254 TABLE 225 JAPAN: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 255 TABLE 226 JAPAN: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 255 11.4.2 CHINA 256 11.4.2.1 Opportunities for growth in China hampered by long product approval and registration processes 256 TABLE 227 CHINA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 257 TABLE 228 CHINA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 257 TABLE 229 CHINA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 258 TABLE 230 CHINA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 258 TABLE 231 CHINA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 259 TABLE 232 CHINA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 259 TABLE 233 CHINA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 260 TABLE 234 CHINA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 260 TABLE 235 CHINA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 261 TABLE 236 CHINA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 261 11.4.3 INDIA 262 11.4.3.1 Growing medical tourism and healthcare infrastructure will drive use of immunoassays in India 262 TABLE 237 INDIA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 263 TABLE 238 INDIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 263 TABLE 239 INDIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 264 TABLE 240 INDIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 264 TABLE 241 INDIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 265 TABLE 242 INDIA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 265 TABLE 243 INDIA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 266 TABLE 244 INDIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 266 TABLE 245 INDIA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 267 TABLE 246 INDIA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 267

Report Title: Immunoassay Market by Product (Reagents & Kits, Analyzers), Technology (ELISA, Rapid Test, Western Blotting, ELISPOT), Specimen (Blood, Saliva), Application (Infectious Diseases, Oncology), End User (Hospitals & Clinics) - Global Forecasts to 2027


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

2023 What's Next for Vietnam Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Vietnam Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Venezuela Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Venezuela Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for US Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for US Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Uruguay Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Uruguay Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for United Arab Emirates Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for United Arab Emirates Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Ukraine Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Ukraine Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM